Allergy and Immunology Vol. III
Three topics, 45 cases — the volume's full planned scope. Choose one below to browse its cases.
X-linked SCID gene therapy versus haploidentical transplant, treating active infection in a SCID infant awaiting transplant, immunosuppressing refractory ITP in CVID, GLILD therapy with no agreed standard, X-linked agammaglobulinemia trough targets, specific antibody deficiency prophylaxis thresholds, chronic granulomatous disease transplant timing, Wiskott-Aldrich transplant urgency, off-label dupilumab in hyper-IgE syndrome, DOCK8 deficiency transplant referral, rituximab-induced secondary hypogammaglobulinemia, Fontan-associated protein-losing enteropathy dosing, and IVIG-to-SCIG conversion
Colchicine-resistant familial Mediterranean fever, periodic fever syndrome diagnosis before genetic confirmation, PFAPA treatment tradeoffs, drug-induced hypersensitivity reactions (infliximab, vasculitis, checkpoint-inhibitor colitis, vaccine angioedema), CRMO escalation, adult-onset Still's disease, VEXAS syndrome, CAPS/NOMID therapy selection by phenotype and age, IgG4-related disease, IVIG-resistant Kawasaki disease, anti-TNF-induced lupus, interferonopathy, and Schnitzler syndrome
Live-vaccine timing after B-cell-depleting biologics, rapid drug desensitization protocol selection, perioperative JAK-inhibitor hold intervals, venom immunotherapy with concurrent beta-blockade, updosed antihistamine therapy limits, cumulative glucocorticoid burst exposure, biosimilar substitution, epinephrine autoinjector access and cost, epinephrine use on MAOIs, renal dose-adjustment thresholds, untested dual-biologic combinations, allergen selection under limited immunotherapy tolerance, pharmacogenomic screening before allopurinol, anti-drug antibody-driven secondary loss of response, and extended first-dose observation windows